Zusammenfassung
Vor hundert Jahren äußerte der Vater der Neurochemie, J. L. W. Thudichum, eine Prophezeiung: „Es werde sich zeigen, daß die bedeutenden Gehirnerkrankungen von spezifischen Veränderungen des Neuro- plasmas begleitet werden und diese derzeit verborgenen Störungen definierbar und einer präzisen Behandlung zugänglich werden“ [1].
Die in diesem Bericht genutzten Daten stammen aus Untersuchungen, die zum Teil durch Gelder aus dem NIH Grant Nr. NS-11631-8 unterstützt wurden.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
Drohkin, D. L., Thudichum, J. L. W.: Chemist of the brain. Philadelphia: University of Pennsylvania Press. 1958.
Birkmayer, W., Hornykiewicz, O.: Der L-3–4-Dioxyphenylalanin- (DOPA-)Effekt bei der Parldnson-Aldnese. Wien. klin. Wschr. 45, 787 (1961).
Barbeau, A.: Biochemistry of Parkinson’s disease. In: Proceedings of the Seventh International Neurological Congress, Rome Società Grafica Romana 2, 925–927 (1961).
Cotzias, G. C., Van Woert, M. H., Schiffer, L. M.: Aromatic Amino Acids and Modification of Parkinsonism. New Eng. J. Med. 276, 374–379 (1967).
Yahr, M. D., Duvoisin, R. C, Schear, M. J., Barrett, R. E., Hoehn, M, M.: Treatment of Parkinsonism with Levodopa. Arch. Neur. 21 (1969).
Yahr, M. D.: Treatment of Parkinson disease. In: Current Concepts of Parkinson Disease and Related Disorders (Yahr, M. D., Hrsg.), S. 161–171. Elsevier,. 1981.
Yahr, M. D.: Pharmacological treatment of Parkinson’s disease in early and late phases. In: Research Progress in Parldnson’s Disease (Rose, F. C, Capildeo, R., Hrsg.) 30, S. 233–240. ,Pitman Medical. 1981.
Yahr, M.D.: Evaluation of long-term therapy in Parkinson’s disease: mortality and therapeutic efficacy. In: Advances in Parkinsonism, S. 435–444. Basel: Editiones Roches. 1975.
Diamond, S. G., Markham, C. H., Treciokas, L.J.: Long-term experience with L-dopa: efficacy, progression and mortality. In: Advances in Parkinsonism, S. 444–455. Basel: Editiones Roches. 1975.
Bauer, R.B., Stevens, C., Reveno, W.S., Rosenhaum, H.: L-dopa treatment of Parkinson’s disease: A ten-year follow-up study. J. Amer. Geriat. Soc. 322–326 (1980).
Cohen, G.: The Pathobiology of Parkinson’s disease: biochemical aspects of dopamine neuron science. In: Neural Transm., Suppl. 19, S.89. Wien-New York: Springer. 1983.
Cohen, G, Heikkila, R. E, Macnamee, D.: The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid and related cytoxic agents. J. Biol. Chem. 249, S. 2447–2452 (1974).
Langston, J. W., Ballard, P.: Chronic Parkinsonism in humans due to a product of meperidineanalog synthesis. Science 219, S. 979–980 (1983).
Barheau, A., Roy, M., Langston, J. W.: Neurological consequence of industrial exposure to l-methyl-4-phenyl-l, 2, 3,6-tetrahydropyridine. (Letters to the Editor.) Lancet 1985, 747.
Cohen, G., Pasik, P., Cohen, B., Leist, A., Mytilineou, C, Yahr, M.D.: Pargyline and deprenyl prevent the neurotoxicity of l-methyl-4- phenyl-1,2, 3, 6-tetrahydropyridine (MPTP) in monkeys. Eur. J. Phar- mac. 106, S. 209–210 (1984).
Mytilineou, C., Cohen, G.: l-methyl-4-phenyl-l, 2, 3, 6-tetrahydropyridine destroys dopamine neurons in explants of rat embryo mesencephalon. Science 225, S. 529–531 (1984).
Javitch, J.A., D’Amato, R. J., Strittmatter, S. M., Snyder, S. H.: Parldn- sonisminducing neurotoxin, N-methyl-4-phenyl-l, 2, 3, 6-tetrahy- dropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explians selective toxicity. Proc. Natl. Acad. Sci. 82, S. 2173–2177 (1985).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Springer-Verlag/Wien
About this chapter
Cite this chapter
Yahr, M.D. (1985). Aspekte zur Pathogenese und Behandlung des Parkinsonismus. In: Riederer, P., Umek, H. (eds) L-Dopa-Substitution der Parkinson-Krankheit. Springer, Vienna. https://doi.org/10.1007/978-3-7091-8822-4_11
Download citation
DOI: https://doi.org/10.1007/978-3-7091-8822-4_11
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-8823-1
Online ISBN: 978-3-7091-8822-4
eBook Packages: Springer Book Archive